FacebookTwitterInstagramEmail
Close

Author: Mandy Spencer

Why is understanding hypermetabolism important in ALS outcomes?

Why is understanding hypermetabolism important in ALS outcomes?

Mandy Spencer

Reading Time: 7 minutes Shyuan’s talk was titled ‘Investigating the role of hypermetabolism in ALS’ (C06 in the abstract book) and discussed the research being carried out by her team to try and understand the mechanisms driving hypermetabolism in ALS and what hypermetabolism means clinically for people living with the disease. This blog details Shyuan’s work and looks closely at her observations on hypermetabolism in relation to ALS.

Improving clinical endpoints to help improve MND clinical trial outcomes

Improving clinical endpoints to help improve MND clinical trial outcomes

Mandy Spencer

Reading Time: 5 minutes What is a clinical endpoint?

A clinical endpoint is used to determine if the drug that is being tested in a clinical trial is beneficial to the people it is intended to treat – those effects that directly measure how a participant in the trial feels, functions or survives.

To determine a clinical endpoint, it is important to understand how a person with a disease feels and functions, and this is well understood in MND. So, a drug that improves any of these could be seen to be beneficial.

Symposium Spotlight: Biomarkers in MND – improving drug development and clinical trial design

Symposium Spotlight: Biomarkers in MND – improving drug development and clinical trial design

Mandy Spencer

Reading Time: 4 minutes Diagnosing disease faster, accurately predicting disease progression, assessing the ability of a new drug to reach its target – I think we’d all agree that these three things are essential requirements for treating all diseases. But how can we achieve this? The answer may lie in biomarkers. In his plenary talk at last year’s International…

What next for edaravone?

What next for edaravone?

Mandy Spencer

Reading Time: 4 minutes This is blog number 21 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). At present, the only…

Update on clinical trials – part 2

Update on clinical trials – part 2

Mandy Spencer

Reading Time: 4 minutes This is blog number 20 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). Clinical trials are research…

Update on clinical trials – part 1

Update on clinical trials – part 1

Mandy Spencer

Reading Time: 5 minutes This is blog number 19 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). Clinical trials are research…

Drug discovery and development

Drug discovery and development

Mandy Spencer

Reading Time: 4 minutes This is blog number 17 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). Drug discovery can be…